The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial

Annals of the Rheumatic Diseases

Volumn 68, Issue 11, 2009, Pages 1708-1714

  Schiff, M ^a   Pritchard, C ^b   Huffstutter, J E ^c   Rodriguez Valverde, V ^d   Durez, P ^e   Zhou, X ^f   Li, T ^f   Bahrt, K ^f   Kelly, S ^f   Le Bars, M ^f   Genovese, M C ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b Rheumatology Specialty Center   (United States)

^c Arthritis Associates   (United States)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f BRISTOL MYERS SQUIBB   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK HERNIA; LOBAR PNEUMONIA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; REMISSION; RHEUMATOID ARTHRITIS; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UTERUS CANCER; BLOOD; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HOSPITALIZATION; METABOLISM; MIDDLE AGED; NEOPLASM; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449709528     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.099218     Document Type: Article

References (17)

1. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)
2. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
3. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
4. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
5. ClinicalTrials.gov. Study of abatacept (BMS-188667) in subjects with active rheumatoid arthritis on background non-biologic DMARDs (disease modifying antirheumatic drugs) who have an inadequate response to anti-TNF therapy. Series 2007. http://www.clinicaltrials.gov/ct/show/NCT00124982?order=2 ClinicalTrials.gov (accessed Dec 2008).
6. Pisano D, Mantus D, Pisano P. FDA regulatory affairs: a guide for prescription drugs, medical devices and biologics. Boca Raton, Florida: CRC Press, 2003.
7. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
8. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145
9. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992;5:119-129
10. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-1850
11. Vrijhoef HJ, Diederiks JP, Spreeuwenberg C, et al. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:419-422 (Pubitemid 36469731)
12. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-1255 (Pubitemid 39359299)
13. Wells GA, Becker J-CP, Teng J, et al. Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR. Ann Rheum Dis. Published Online First: 19 May 2008. doi:10.1136/ard.2007.084459.
14. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560 (Pubitemid 23102493)
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
16. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806 (Pubitemid 44497758)
17. Keystone E. Abatacept provides clinical benefits in rheumatoid arthritis (RA) patients who previously demonstrated a lack of response or no response to one or more anti-TNF therapies. Arthritis Rheum 2006;54(Suppl 9):406.